- Iovance Biotherapeutics (NASDAQ:IOVA +5.1%) is up on below-average volume. After the close, it will release Q2 results.
- Investors may be taking positions expecting management to announce updated interim data from one or more its Phase 2 studies of tumor infiltrating lymphocytes in head and neck cancer, melanoma, cervical cancer and non-small cell lung cancer.
Iovance Bio up 5% ahead of Q2 results
Recommended For You
More Trending News
About IOVA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
IOVA | - | - |
Iovance Biotherapeutics, Inc. |